For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

According to a Research Report "Global Agriculture Industry Outlook 2029 - A Look ahead at The Industry Landscape" Published ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Biohacking has moved from niche experiments to a global movement reshaping how we think about human potential. With ...

This study presents an optimized CRISPR-Cas12a system for large-scale genetic screening, revealing critical genes involved in ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get ...